NetworkNewsBreaks Archive - Page 2066 of 2140

TuesdayApr 04, 2017 3:49 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances PRO 140 to Provide a Better Quality of Life for HIV Patients

More than 34 million people have died from HIV since it was first discovered in 1981, according to Healthline (http://nnw.fm/i9ptS). Although there is no known cure for the disease, CytoDyn Inc. (OTCQB: CYDY) is advancing its drug candidate toward providing a better life for HIV patients. “PRO 140 is currently one of the most advanced experimental monoclonal antibodies for HIV treatment, and CYDY believes that it will be beneficial to patients with complicating issues, such as those with single or multi-drug resistant viruses or those who have difficulty sticking to a daily drug regimen, as well as those who can’t…

TuesdayApr 04, 2017 3:48 pm

NetworkNewsBreaks – ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) Results from New Studies Match Previous Findings, CRV431 Targets Hepatitis B Surface Antigen (HBsAg)

ContraVir Pharmaceuticals (NASDAQ: CTRV) this morning released results from new studies that provide insight into the mechanism of action (MOA) of its hepatitis B virus CRV431. The new studies show that CRV431 potently blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein. The new information could explain previous findings that the drug reduces HBsAg. High levels of HBsAg in HBV-infected patients is a predictor for progression of disease, including liver fibrosis, cirrhosis, and cancer. “Our finding that CRV431 targets hepatitis B surface antigen is promising because reducing or eradicating…

TuesdayApr 04, 2017 11:19 am

NetworkNewsBreaks – Evoke Pharma (NASDAQ: EVOK) Moves Forward with Comparative Exposure PK Trial for Gimoti NDA Following Type A Meeting with FDA

Evoke Pharma (NASDAQ: EVOK) shares rallied as much as 11% this morning after the company provided details of its positive Type A meeting with the U.S. Food and Drug Administration (FDA). Evoke met with the FDA to finalize the design of the pivotal comparative exposure pharmacokinetic (PK) trial and to reach agreement on additional aspects of the Chemistry, Manufacturing & Controls (CMC) section of the New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. The pivotal comparative exposure PK trial will be conducted in healthy volunteers to demonstrate…

TuesdayApr 04, 2017 11:17 am

NetworkNewsBreaks – Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) Receives Patent for TSC in Five Hypoxia-Related Indications; Shares Rally

Shares of Diffusion Pharmaceuticals (NASDAQ: DFFN) surged as much as 23% this morning after the company announced that the U.S. Patent and Trademark Office (USPTO) has issued a key patent for the company’s lead drug candidate, trans sodium crocetinate (TSC). Diffusion’s existing patents currently include the use of TSC in oncology, stroke and neurodegenerative disease indications. The new patent increases coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome. “Receiving the patent from the USPTO validates…

TuesdayApr 04, 2017 9:42 am

NetworkNewsBreaks – Bollente Companies, Inc. (BOLC) Announces Selection of trutankless® as Exclusive Water Heating Solution of Cullum Homes

Bollente Companies, Inc. (OTCQB: BOLC) this morning announced that its innovative trutankless® line of smart electric tankless water heaters has been selected as the exclusive water heating solution for luxury communities constructed by award-winning Arizona home builder Cullum Homes. “trutankless is the only whole-home water heating solution I recommend,” Rod Cullum, owner and founder of Cullum Homes, stated in the news release. “I have used trutankless for years in my own home, where my family and I enjoy reliable, endless hot water. It only makes sense that I would offer the same quality and energy-efficient technology in the homes I…

MondayApr 03, 2017 1:43 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: KPAY 29.44% – News: Moves on momentum from recent launch of “No Administration Fee” campaign for Perusahaan Listrik Negara YTEN 14.10% – News: Presenting live at VirtualInvestorConferences.com on April 6 GRWG 13.68% – News: Posts FY 2016 financial results EBIO 12.27% – News: Presents new preclinical data with VB4-845 at AACR Annual Meeting 2017 NBEV 10.90% – News: Posts FY 2016 financial results, reports multiple new acquisitions ESDI 10.27% – News: Posts FY 2016…

MondayApr 03, 2017 1:41 pm

NetworkNewsBreaks – Cancer Genetics, Inc. (NASDAQ: CGIX) Enters Strategic Partnership with Mendel.ai to Employ Artificial Intelligence in Precision Medicine

Cancer Genetics (NASDAQ: CGIX) (“CGI”) has entered into a strategic partnership with Mendel Health, an artificial intelligence company focused on using the Mendel.ai deep-learning engine to accelerate and constantly update clinical trial matching for patients. The companies will be collaborating to integrate Mendel.ai capabilities for clinicians, oncologists and pathologists, as well as cancer centers and hospitals with CGI’s disease-focused reports and testing results. The companies anticipate that initial, early-access partners will be using the system during the second quarter of 2017 with a more extensive rollout through the third and fourth quarters of this year. “Artificial intelligence has advanced and…

MondayApr 03, 2017 1:37 pm

NetworkNewsBreaks – MTBC (NASDAQ: MTBC) Launches Accountable Care Organization Analytics Module

MTBC (NASDAQ: MTBC) this morning announced the launch of its most recent addition to its business intelligence and analytics platform, the accountable care organization (ACO) analytics module. This launch marks MTBC's continued growth into larger groups and new practice settings. The company's clinical and practice management solutions are currently leveraged by thousands of healthcare practices throughout the country. "We remain committed to providing healthcare organizations with the tools they need to optimize health outcomes and achieve better financial results, and this most recent addition to our ecosystem of business intelligence and analytics tools is another example of our commitment in…

MondayApr 03, 2017 12:25 pm

NetworkNewsBreaks – Biocept, Inc. (NASDAQ: BIOC) Engages ROTH Capital Partners as Lead Placement Agent in $9.3M Registered Direct; Enters Agreement with Oregon Health & Sciences University

Biocept (NASDAQ: BIOC) recently completed a sale of 4,320,000 shares of common stock at a price of $2.15 per share, with ROTH Capital Partners as lead placement agent in the offering. The gross proceeds of the offering are expected to be approximately $9.3 million, which the company intends to use the proceeds for working capital and general corporate purposes. Additionally, the company said today that is has entered into a Preferred Provider Collaboration and Services Agreement with Oregon Health & Sciences University on behalf of the OHSU Knight Cancer Institute (collectively OHSU). Per the multiphase agreement, OHSU is granted the…

MondayApr 03, 2017 12:22 pm

NetworkNewsBreaks – Interpace Diagnostics (NASDAQ: IDXG) Receives European Patent Approval For Core Technology of its ThyraMIR® microRNA Classifier

Interpace Diagnostics (NASDAQ: IDXG) shares are up 7% after the company said this morning that the European Patent Office granted it a patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of the company's ThyraMIR® microRNA Classifier. Interpace intends to validate and enforce this Intellectual Property in select European countries going forward. "We are pleased to announce the approval of this patent by the European Patent Office as it provides a basis for introducing our first product to the European market as part of our international expansion plan. Importantly, this patent…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks